Related Experiment Video
Updated: Aug 17, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases
Hye Sook Jung1, Dong Wook Kim, Young Suk Jo
1Laboratory of Endocrine Cell Biology, National Research Laboratory Program, Department of Internal Medicine, Chungnam National University School of Medicine, 640 Daesadong Chungku, Daejeon 301-721, Korea.
Abstract:
Papillary thyroid carcinoma (PTC) is a heterogenous disorder characterized by unique gene rearrangements and gene mutations that activate signaling pathways responsible for cellular transformation, survival, and antiapoptosis. Activation of protein kinase B (PKB) and its downstream signaling pathways appears to be an important event in thyroid tumorigenesis. In this study, we found that the thyroid-specific oncogenic RET/PTC tyrosine kinase is able to phosphorylate PKB in vitro and in vivo. RET/PTC-transfected cells showed tyrosine phosphorylation of endogenous and exogenous PKB, which was independent of phosphorylation of T308 and S473 regulated by the upstream kinases phosphoinositide-dependent kinase-1 and -2, respectively. The PKB Y315 residue, which is known to be phosphorylated by Src tyrosine kinase, was also a major site of phosphorylation by RET/PTC. RET/PTC-mediated tyrosine phosphorylation results in the activation of PKB kinase activity. The activation of PKB by RET/PTC blocked the activity of the forkhead transcription factor, FKHRL1, but a Y315F mutant of PKB failed to inhibit FKHRL1 activity. In summary, these observations suggest that RET/PTC is able to phosphorylate the Y315 residue of PKB, an event that results in maximal activation of PKB for RET/PTC-induced thyroid tumorigenesis.
Insights
The RET/PTC oncogene activates protein kinase B (PKB) by phosphorylating its Y315 residue, a key event in papillary thyroid carcinoma (PTC) development. This activation promotes thyroid tumorigenesis by inhibiting FKHRL1.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Papillary thyroid carcinoma (PTC) is a complex cancer driven by genetic alterations activating signaling pathways.
- Protein kinase B (PKB) signaling is crucial in thyroid cancer development.
Purpose of the Study:
- To investigate the role of the RET/PTC oncogene in PKB activation.
- To identify the specific mechanisms by which RET/PTC influences PKB activity and thyroid tumorigenesis.
Main Methods:
- In vitro and in vivo experiments using RET/PTC-transfected cells.
- Analysis of PKB phosphorylation at specific residues (Y315, T308, S473).
- Assessment of PKB kinase activity and its effect on the transcription factor FKHRL1.
Main Results:
- RET/PTC directly phosphorylates PKB at the Y315 residue, independent of upstream kinases regulating T308 and S473.
- This RET/PTC-mediated tyrosine phosphorylation at Y315 leads to maximal PKB activation.
- Activated PKB by RET/PTC inhibits the activity of the transcription factor FKHRL1.
Conclusions:
- RET/PTC oncogene plays a critical role in papillary thyroid carcinoma pathogenesis by activating PKB.
- Phosphorylation of PKB at Y315 by RET/PTC is a key step for PKB activation and subsequent inhibition of FKHRL1.
- Targeting the RET/PTC-PKB signaling axis may offer therapeutic strategies for PTC.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Receptor Tyrosine Kinases
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...